Company profile for Phoenix Molecular Designs

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Phoenix Molecular Designs is a clinical-stage biopharmaceutical company focused on developing precise cancer therapeutics. Their lead candidate, PMD-026, is a first-in-class oral RSK inhibitor targeting triple-negative breast cancer (TNBC). In February 2022, they completed patient enrollment for a Phase 1b monotherapy clinical trial of PMD-026, marking a significant milestone in advancing treatment options for TNBC patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
8755 Ash St. Suite 1 Vancouver, V6P 6T3
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/02/20/3030106/0/en/Phoenix-Molecular-Designs-Dosed-First-Patient-in-Dauntless-1-a-Phase-2-Clinical-Trial-of-PMD-026-in-Combination-with-Fulvestrant-for-RSK2-high-Breast-Cancer.html

GLOBENEWSWIRE
20 Feb 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty